These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35702728)

  • 1. Astrocytic function is associated with both amyloid-β and tau pathology in non-demented
    Spotorno N; Najac C; Stomrud E; Mattsson-Carlgren N; Palmqvist S; van Westen D; Ronen I; Hansson O
    Brain Commun; 2022; 4(3):fcac135. PubMed ID: 35702728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
    Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
    Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
    Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
    Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
    Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.
    Aksman LM; Oxtoby NP; Scelsi MA; Wijeratne PA; Young AL; Alves IL; Collij LE; Vogel JW; Barkhof F; Alexander DC; Altmann A;
    Brain; 2023 Dec; 146(12):4935-4948. PubMed ID: 37433038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's Disease.
    Hirata K; Matsuoka K; Tagai K; Endo H; Tatebe H; Ono M; Kokubo N; Oyama A; Shinotoh H; Takahata K; Obata T; Dehghani M; Near J; Kawamura K; Zhang MR; Shimada H; Yokota T; Tokuda T; Higuchi M; Takado Y
    Ann Neurol; 2023 Sep; ():. PubMed ID: 37703428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
    Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
    Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
    Nemes S; Logan PE; Manchella MK; Mundada NS; La Joie R; Polsinelli AJ; Hammers DB; Koeppe RA; Foroud TM; Nudelman KN; Eloyan A; Iaccarino L; Dorsant-Ardón V; Taurone A; Thangarajah M; Dage JL; Aisen P; Grinberg LT; Jack CR; Kramer J; Kukull WA; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Vemuri P; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Womack KB; Wolk DA; Rabinovici GD; Carrillo MC; Dickerson BC; Apostolova LG;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S49-S63. PubMed ID: 37496307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors.
    Cooper JG; Ghodsi M; Stukas S; Leach S; Brooks-Wilson A; Wellington CL
    Alzheimers Dement; 2024 Jun; 20(6):4373-4380. PubMed ID: 38752508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of liver function markers and apolipoprotein E ε4 with pathogenesis and cognitive decline in Alzheimer's disease.
    Han SW; Lee SH; Kim JH; Lee JJ; Park YH; Kim S; Nho K; Sohn JH
    Front Aging Neurosci; 2024; 16():1411466. PubMed ID: 39114318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of
    Shang L; Dong L; Huang X; Wang T; Mao C; Li J; Wang J; Liu C; Gao J
    Front Aging Neurosci; 2023; 15():1119070. PubMed ID: 37065463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.
    Salvadó G; Grothe MJ; Groot C; Moscoso A; Schöll M; Gispert JD; Ossenkoppele R;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2212-2224. PubMed ID: 33521872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
    Bonham LW; Desikan RS; Yokoyama JS;
    Acta Neuropathol Commun; 2016 Jun; 4(1):65. PubMed ID: 27357286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study.
    Yang HS; Yu L; White CC; Chibnik LB; Chhatwal JP; Sperling RA; Bennett DA; Schneider JA; De Jager PL
    Lancet Neurol; 2018 Sep; 17(9):773-781. PubMed ID: 30093249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.
    Konijnenberg E; Tijms BM; Gobom J; Dobricic V; Bos I; Vos S; Tsolaki M; Verhey F; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Frölich L; Lovestone S; Streffer J; Bertram L; Blennow K; Teunissen CE; Veerhuis R; Smit AB; Scheltens P; Zetterberg H; Visser PJ
    Alzheimers Res Ther; 2020 May; 12(1):65. PubMed ID: 32460813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.
    Peretti DE; Boccalini C; Ribaldi F; Scheffler M; Marizzoni M; Ashton NJ; Zetterberg H; Blennow K; Frisoni GB; Garibotto V
    Brain; 2024 Jun; ():. PubMed ID: 38940331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Effects of the Interaction Between the Education and APOE ε4 Allele on Amyloid-beta Retention and Memory Performances in Cognitively Normal Older Adults and Alzheimer's Disease Patients.
    Kang DW; Wang SM; Na HR; Lee CU; Baek IH; Lim HK
    Curr Alzheimer Res; 2020; 17(11):1023-1032. PubMed ID: 33372875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.